Steadybase.

First Tracks Biotherapeutics, Inc.

Website Investor relations LinkedIn
  • TRAX ยท Nasdaq
  • Pharmaceutical Preparations
  • San Diego, CA
  • CIK 0002091349

Updated from SEC filings through

Top things to know

Next earningsFebruary 2, 2027Estimated from past filings
Latest 8-KResults of operations and financial conditionFiled November 3, 2026

Executives

What leadership is saying

“ANB033, a subcutaneously administered CD122 antagonist designed to inhibit signaling of both IL-15 and IL-2 on immune cells, demonstrated statistically significant protection against gluten-induced intestinal damage and symptoms and was well tolerated in the Phase 1b gluten-challenge cohort. These data support our plans to progress ANB033 into late-stage development in 2027 in celiac disease as a potential treatment to prevent both acute symptoms and intestinal damage from gl”

Daniel Faga, President and chief executive officer
Earnings press release (8-K Ex. 99.1), filed November 3, 2026

First Tracks Biotherapeutics, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in San Diego, CA. It trades as TRAX on Nasdaq. Daniel Faga is President and chief executive officer.

Five-year financials

We have no annual financials for this company yet.

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Daniel Faga Daniel Faga President and chief executive officer 8-K, November 3, 2026
Ajim Tamboli Ajim Tamboli
Chief Financial Officer
Chief Financial Officer Form 4, May 14, 2026
Benjamin Stone
Chief Business Officer at First Tracks Biotherapeutics
Chief Business Officer Form 4, August 18, 2026
Paul F. Lizzul Chief Medical Officer Form 4, August 18, 2026

What First Tracks Biotherapeutics, Inc. does

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator.com or follow us on LinkedIn .

Press release "About" paragraph, 10-K for the year ending October 15, 2026

Shares and governance

Shares outstanding 42.0 million (as of October 29, 2026) 10-Q, November 3, 2026
Reportable segments 1 (period ending September 30, 2026) 10-Q, November 3, 2026

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
September 2, 2026 J. Anthony Ware
Director
Sale 39,265 $1.8M Form 4, September 4, 2026

Recent 8-K events

  • 8-K filed 2026-11-03
    • Item 2.02 Results of operations and financial condition (earnings release)
  • 8-K filed 2026-10-20
    • Item 1.01 Entry into a material definitive agreement
  • 8-K filed 2026-10-15
    • Item 1.01 Entry into a material definitive agreement
    • Item 3.02 Unregistered sales of equity securities
    • Item 7.01 Regulation FD disclosure
  • 8-K filed 2026-10-13
    • Item 7.01 Regulation FD disclosure
    • Item 8.01 Other events
  • 8-K filed 2026-08-12
    • Item 2.02 Results of operations and financial condition (earnings release)
  • 8-K filed 2026-06-22
    • Item 1.01 Entry into a material definitive agreement
  • 8-K filed 2026-05-14
    • Item 2.02 Results of operations and financial condition (earnings release)
  • 8-K filed 2026-04-20
    • Item 1.01 Entry into a material definitive agreement
    • Item 2.01 Completion of acquisition or disposition of assets
    • Item 3.02 Unregistered sales of equity securities
    • Item 3.03 Material modification to rights of security holders
    • Item 5.01 Changes in control of registrant
    • Item 5.02 Departure or appointment of directors or officers; compensation
    • Item 5.03 Amendments to articles or bylaws; change in fiscal year
    • Item 8.01 Other events
  • 8-K filed 2026-04-03
    • Item 7.01 Regulation FD disclosure

Frequently asked questions about First Tracks Biotherapeutics, Inc.

What does First Tracks Biotherapeutics, Inc. do?
In its own words, from Item 1 of its 10-K: "First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator.com or follow us on LinkedIn ."
Who is the CEO of First Tracks Biotherapeutics, Inc.?
Daniel Faga, President and chief executive officer, as named in a 8-K filed November 3, 2026.
Who is the CFO of First Tracks Biotherapeutics, Inc.?
Ajim Tamboli, Chief Financial Officer, as named in a 4 filed May 14, 2026.
Where is First Tracks Biotherapeutics, Inc. headquartered?
San Diego, CA.
What is First Tracks Biotherapeutics, Inc.'s stock ticker?
TRAX on Nasdaq.
What industry is First Tracks Biotherapeutics, Inc. in?
Pharmaceutical Preparations, SIC code 2834.
What is First Tracks Biotherapeutics, Inc.'s website?
firsttracksbio.com. Investor relations: https://ir.firsttracksbio.com/news-events/news-releases.
When does First Tracks Biotherapeutics, Inc. report earnings next?
February 2, 2027. This is an estimate from past filing dates, not a confirmed date.
Is First Tracks Biotherapeutics, Inc. a public company?
Yes. First Tracks Biotherapeutics, Inc. files with the SEC under CIK 0002091349 and trades as TRAX.
How many shares of First Tracks Biotherapeutics, Inc. are outstanding?
42.0 million shares as of October 29, 2026, from its 10-Q filed November 3, 2026.
How many business segments does First Tracks Biotherapeutics, Inc. report?
1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 3, 2026.
Have First Tracks Biotherapeutics, Inc. insiders traded stock recently?
Since September 2, 2026, officers and directors reported 1 open-market sale worth about $1.8M and 0 purchases on Forms 4 and 5. The most recent: J. Anthony Ware (Director) sold 39,265 shares on September 2, 2026.